Summary of key points, looking forward to the official announcement, these seems really positive:
- 40% response rate 5 CR and 1 PR.
- 60% of EMD patients responded, with 20% of AML patients having EMD
- R/R AML and heavily pretreated, Median 4 lines of treatment and 40% >4
- 2 of 5 Bridged to stem cell transplant, 2 with complete remission.
- 3 of 5 Bridged to stem cell transplant, 1 passed due to host rejection, 1 infection and 1 relapse
- Infection of patients with pre-treatment limited patient evaluation.
- Dr Nagler considers it to be IMPRESSIVE and requires further evaluation with Venetoclax
- We know Bisantrene synergises with Venetoclax.
- No Cardiotoxicity observed in treatment.
- Note the board member disclosures who had their hand in the abstract.
Full steam ahead!
ASH2023 - Sheba 2.0, page-4
-
- There are more pages in this discussion • 153 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |